StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Equities researchers at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Up 0.7 %

Shares of TXMD opened at $1.41 on Wednesday. The company’s 50 day moving average price is $1.55 and its 200 day moving average price is $1.75. TherapeuticsMD has a 52 week low of $1.15 and a 52 week high of $2.99.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP grew its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. 30.74% of the stock is currently owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.